<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39312834</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>279</Volume><PubDate><Year>2024</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Exploration of isatin-based inhibitors of SARS-CoV-2 Nsp15 endoribonuclease.</ArticleTitle><Pagination><StartPage>116886</StartPage><MedlinePgn>116886</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2024.116886</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(24)00767-0</ELocationID><Abstract><AbstractText>The global health crisis caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) urges the development of new antiviral agents with broad coronavirus coverage. Due to its key role in viral evasion from the host innate immune response, the coronavirus Nsp15 uridine-specific endoribonuclease (EndoU) is of high interest as a drug target. Considering that the isatin scaffold is well-known for its versatile pharmacological properties, we synthesized and evaluated a series of compounds carrying an isatin core. The initial compounds were selected on the basis of in silico predictions. After biochemical assays showed moderate inhibition of SARS-CoV-2 EndoU-mediated RNA cleavage, structural analogues were rationally designed to enhance the interaction with the target. This included the incorporation of a nitrile group since this dipole can improve ADME and facilitate polar interactions with proteins and can operate as hydroxy or carboxy surrogate. A straightforward solvent free and green, microwave-assisted synthetic process was established to achieve the development of the different target compounds. The best compound exhibited inhibitory activity in enzymatic EndoU assays, and reduced the SARS-CoV-2 viral RNA load by almost 68,000-fold in the low micromolar range similarly to the established antiviral agent GS-441524.</AbstractText><CopyrightInformation>Copyright Â© 2024. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rampias</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biomedical Research Foundation Academy of Athens, 4 Soranou Efesiou, 115 27, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Ioannina, Department of Chemistry, Section of Organic Chemistry and Biochemistry, Ioannina, GR-45110, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevaert</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kravariti</LastName><ForeName>Lara</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, Section of Biochemistry and Molecular Biology, Department of Biology, Panepistimiopolis, 15701, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Loy</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandeput</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgrignani</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research In Biochemistry (IRB), Universita' della Svizzera Italiana, Via Chiesa 5, Bellinzona, 6500, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippidou</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biomedical Research Foundation Academy of Athens, 4 Soranou Efesiou, 115 27, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Research In Biochemistry (IRB), Universita' della Svizzera Italiana, Via Chiesa 5, Bellinzona, 6500, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samiotaki</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming, 16672, Vari, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzakos</LastName><ForeName>Eleftherios Paraskevas</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, Section of Biochemistry and Molecular Biology, Department of Biology, Panepistimiopolis, 15701, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Research In Biochemistry (IRB), Universita' della Svizzera Italiana, Via Chiesa 5, Bellinzona, 6500, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naesens</LastName><ForeName>Lieve</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sideris</LastName><ForeName>Diamantis C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, Section of Biochemistry and Molecular Biology, Department of Biology, Panepistimiopolis, 15701, Athens, Greece. Electronic address: dsideris@biol.uoa.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzakos</LastName><ForeName>Andreas G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>University of Ioannina, Department of Chemistry, Section of Organic Chemistry and Biochemistry, Ioannina, GR-45110, Greece. Electronic address: atzakos@uoi.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>82X95S7M06</RegistryNumber><NameOfSubstance UI="D007510">Isatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004722">Endoribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C000657925">nidoviral uridylate-specific endoribonuclease</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007510" MajorTopicYN="Y">Isatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004722" MajorTopicYN="Y">Endoribonucleases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="Y">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of competing interest All authors have approved the final submission to the journal. The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312834</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2024.116886</ArticleId><ArticleId IdType="pii">S0223-5234(24)00767-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>